Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Fierce Pharma Asia—Trump’s generic drug tariffs; Samsung Bio’s $1.8B acquisition; An unusual IPO
Generic drugmakers will face import tariffs in the U.S., President Donald Trump announced this week. Samsung Biologics is pursuing the biggest M&A deal ever for a Korean biopharma company. | Generic drugmakers will face import tariffs in the U.S., President Donald Trump announced this week. Samsung Biologics is pursuing the biggest M&A deal ever for a Korean biopharma company. In an unconventional move, a U.S. biotech is gunning for an IPO in Hong Kong first. And more.
TL;DRAI
Samsung Biologics acquired Swiss CDMO PolyPeptide for $1.8B (Korea's largest pharma M&A) to expand GLP-1 peptide manufacturing. The deal signals biopharma consolidation around obesity therapy, validating CDMO infrastructure as a key strategic M&A target.
811 words~4 min read
